Sign Out
Patients receiving Zefei should be monitored prior to each dose with complete blood count (CBC) including differential and platelet, leukocyte and granulocyte count. Suspension or modification of therapy should be considered when marrow suppression is detected.
Laboratory evaluation of renal and hepatic function should be performed prior to initiation of therapy and periodically thereafter.
Use in pregnancy: Gemcitabine HCl can cause fetal harm when administered to a pregnant woman. If gemcitabine HCl is used during pregnancy, or if the patient becomes pregnant while taking gemcitabine HCl, the patient should be apprised of the potential hazard to the fetus.
